Autolus Therapeutics

General Information
Business:

 

We are a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. Using our broad suite of proprietary and modular T-cell programming technologies, we are engineering precisely targeted, controlled and highly active T-cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells.

 

Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
Employees: 126
Founded: 2017
Contact Information
Address Forest House, 58 Wood Lane, White City, London W12 7RZ, UK
Phone Number +44 20 3829 6230
Web Address http://www.autolus.com
View Prospectus: Autolus Therapeutics
Financial Information
Market Cap $604.4mil
Revenues $1.7 mil (last 12 months)
Net Income $-18.9 mil (last 12 months)
IPO Profile
Symbol AUTL
Exchange NASDAQ
Shares (millions): 8.8
Price range $17.00 - $17.00
Est. $ Volume $150.0 mil
Manager / Joint Managers Goldman Sachs/ Jefferies
CO-Managers Wells Fargo Securities/ William Blair
Expected To Trade: 6/22/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change